

# Karen Canfell

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5479405/karen-canfell-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

226  
papers

4,523  
citations

34  
h-index

58  
g-index

259  
ext. papers

6,228  
ext. citations

5.7  
avg, IF

5.96  
L-index

#	Paper	IF	Citations
226	Evaluating prognostic factors for sex differences in lung cancer survival: findings from a large Australian cohort.. <i>Journal of Thoracic Oncology</i> , <b>2022</b> ,	8.9	2
225	The potential for tailored screening to reduce bowel cancer mortality for Aboriginal and Torres Strait Islander peoples in Australia: Modelling study.. <i>Journal of Cancer Policy</i> , <b>2022</b> , 32, 100325	1	2
224	National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.. <i>BMJ, The</i> , <b>2022</b> , 376, e068582	5.9	2
223	Trends in colon and rectal cancer mortality in Australia from 1972 to 2015 and associated projections to 2040.. <i>Scientific Reports</i> , <b>2022</b> , 12, 3994	4.9	0
222	Accurate categorisation of menopausal status for research studies: a step-by-step guide and detailed algorithm considering age, self-reported menopause and factors potentially masking the occurrence of menopause.. <i>BMC Research Notes</i> , <b>2022</b> , 15, 88	2.3	0
221	Applying utility values in cost-effectiveness analyses of lung cancer screening: A review of methods.. <i>Lung Cancer</i> , <b>2022</b> , 166, 122-131	5.9	0
220	COVID-19 and Cancer Global Modelling Consortium (CCGMC): A global reference to inform national recovery strategies.. <i>Journal of Cancer Policy</i> , <b>2022</b> , 32, 100328	1	0
219	Changes in prostate cancer incidence, mortality and survival in relation to prostate specific antigen testing in New South Wales, Australia.. <i>Cancer Epidemiology</i> , <b>2022</b> , 78, 102159	2.8	
218	Measuring school level attributable risk to support school-based HPV vaccination programs.. <i>BMC Public Health</i> , <b>2022</b> , 22, 822	4.1	0
217	Lynch syndrome testing of colorectal cancer patients in a high-income country with universal healthcare: a retrospective study of current practice and gaps in seven Australian hospitals.. <i>Hereditary Cancer in Clinical Practice</i> , <b>2022</b> , 20, 18	2.3	1
216	Cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study. <i>Lancet Public Health, The</i> , <b>2022</b> , 7, e537-e548	22.4	3
215	Socioeconomic disparities in colorectal cancer survival: contributions of prognostic factors in a large Australian cohort. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 1	4.9	1
214	The IARC Perspective on Cervical Cancer Screening. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 1908-1918	35.2	12
213	Health system costs and days in hospital for colorectal cancer patients in New South Wales, Australia. <i>PLoS ONE</i> , <b>2021</b> , 16, e0260088	3.7	0
212	Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study.. <i>Journal of Medical Screening</i> , <b>2021</b> , 9691413211056777	1.4	2
211	High-Risk Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma Among Non-Indigenous and Indigenous Populations: A Systematic Review. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2021</b> , 165, 23-32	5.5	2
210	Impact of COVID-19-related care disruptions on cervical cancer screening in the United States. <i>Journal of Medical Screening</i> , <b>2021</b> , 28, 213-216	1.4	14

209	Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV control. <i>International Journal of Cancer</i> , <b>2021</b> , 149, 297-306	7.5	1
208	Psychosocial impact of COVID-19 on cancer patients, survivors, and carers in Australia: a real-time assessment of cancer support services. <i>Supportive Care in Cancer</i> , <b>2021</b> , 29, 5463-5473	3.9	14
207	Poor self-rated oral health associated with poorer general health among Indigenous Australians. <i>BMC Public Health</i> , <b>2021</b> , 21, 424	4.1	0
206	Care to Quit: a stepped wedge cluster randomised controlled trial to implement best practice smoking cessation care in cancer centres. <i>Implementation Science</i> , <b>2021</b> , 16, 23	8.4	0
205	Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis. <i>PLoS Medicine</i> , <b>2021</b> , 18, e1003534	11.6	10
204	Psychometric properties of the EQ-5D-5L for aboriginal Australians: a multi-method study. <i>Health and Quality of Life Outcomes</i> , <b>2021</b> , 19, 81	3	0
203	Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 304-314	18.8	38
202	The Future Burden of Head and Neck Cancers Attributable to Modifiable Behaviors in Australia: A Pooled Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2021</b> , 30, 1566-1574	4	0
201	Cancer incidence and cancer death in relation to tobacco smoking in a population-based Australian cohort study. <i>International Journal of Cancer</i> , <b>2021</b> , 149, 1076-1088	7.5	3
200	Birth-cohort estimates of smoking initiation and prevalence in 20th century Australia: Synthesis of data from 33 surveys and 385,810 participants. <i>PLoS ONE</i> , <b>2021</b> , 16, e0250824	3.7	0
199	Effective HPV vaccination coverage in Australia by number of doses and two-dose spacing: What if one or two doses are sufficient?. <i>Tumour Virus Research</i> , <b>2021</b> , 11, 200216		2
198	Working towards a comprehensive understanding of HPV and cervical cancer among Indigenous women: a qualitative systematic review. <i>BMJ Open</i> , <b>2021</b> , 11, e050113	3	2
197	Cohort profile: indigenous human papillomavirus and oropharyngeal squamous cell carcinoma study - a prospective longitudinal cohort. <i>BMJ Open</i> , <b>2021</b> , 11, e046928	3	2
196	A systematic review and meta-analysis of the prevalence of human papillomavirus infection in Indigenous populations - A Global Picture. <i>Journal of Oral Pathology and Medicine</i> , <b>2021</b> , 50, 843-854	3.3	1
195	Population-based utility scores for HPV infection and oropharyngeal squamous cell carcinoma among Indigenous Australians. <i>BMC Public Health</i> , <b>2021</b> , 21, 1455	4.1	1
194	Population-based utility scores for HPV infection and cervical squamous cell carcinoma among Australian Indigenous women. <i>PLoS ONE</i> , <b>2021</b> , 16, e0254575	3.7	
193	Human papillomavirus vaccine effectiveness within a cervical cancer screening programme: cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2021</b> , 128, 532-539	3.7	3
192	Selection of high-risk individuals for esophageal cancer screening: A prediction model of esophageal squamous cell carcinoma based on a multicenter screening cohort in rural China. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 329-339	7.5	12

191	Is it possible to halve the incidence of liver cancer in China by 2050?. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 1051-1065	7.5	18
190	Could HPV Testing on Self-collected Samples Be Routinely Used in an Organized Cervical Screening Program? A Modeled Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2021</b> , 30, 268-277	4	11
189	Health economic evaluation of primary human papillomavirus screening in urban populations in China. <i>Cancer Epidemiology</i> , <b>2021</b> , 70, 101861	2.8	1
188	Moving beyond the stage: how characteristics at diagnosis dictate treatment and treatment-related quality of life year losses for women with early stage invasive breast cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2021</b> , 21, 847-857	2.2	0
187	Alcohol consumption, drinking patterns and cancer incidence in an Australian cohort of 226,162 participants aged 45 years and over. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 513-523	8.7	4
186	Treatment abandonment in children with cancer: Does a sex difference exist? A systematic review and meta-analysis of evidence from low- and middle-income countries. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 895-904	7.5	2
185	Large-scale systematic analysis of exposure to multiple cancer risk factors and the associations between exposure patterns and cancer incidence. <i>Scientific Reports</i> , <b>2021</b> , 11, 2343	4.9	1
184	Prevalence of skin examination behaviours among Australians over time. <i>Cancer Epidemiology</i> , <b>2021</b> , 70, 101874	2.8	1
183	How Well Have Projected Lung Cancer Rates Predicted the Actual Observed Rates?. <i>Asian Pacific Journal of Cancer Prevention</i> , <b>2021</b> , 22, 437-445	1.7	
182	Eliminating cervical cancer in the COVID-19 era.. <i>Nature Cancer</i> , <b>2021</b> , 2, 133-134	15.4	6
181	Eliminating Cervical Cancer: Progress and Challenges for High-income Countries. <i>Clinical Oncology</i> , <b>2021</b> , 33, 550-559	2.8	6
180	Menopausal hormone therapy: Characterising users in an Australian national cross-sectional study. <i>PLoS ONE</i> , <b>2021</b> , 16, e0253725	3.7	0
179	2020 list of human papillomavirus assays suitable for primary cervical cancer screening. <i>Clinical Microbiology and Infection</i> , <b>2021</b> , 27, 1083-1095	9.5	19
178	The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of human papillomavirus screening with self-collection and digital registry support. <i>International Journal of Cancer</i> , <b>2021</b> , 149, 1997-2009	7.5	3
177	The impact of HPV vaccination beyond cancer prevention: effect on pregnancy outcomes. <i>Human Vaccines and Immunotherapeutics</i> , <b>2021</b> , 17, 3562-3576	4.4	0
176	Cancer care disruption and reorganisation during the COVID-19 pandemic in Australia: A patient, carer and healthcare worker perspective. <i>PLoS ONE</i> , <b>2021</b> , 16, e0257420	3.7	7
175	Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis. <i>Preventive Medicine</i> , <b>2021</b> , 151, 106623	4.3	11
174	Differences in school factors associated with adolescent HPV vaccination initiation and completion coverage in three Australian states. <i>Vaccine</i> , <b>2021</b> , 39, 6117-6126	4.1	1

173	The impact of the Covid-19 pandemic on breast cancer early detection and screening. <i>Preventive Medicine</i> , <b>2021</b> , 151, 106585	4.3	10
172	The financial impact of a breast cancer detected within and outside of screening: lessons from the Australian Lifepool cohort. <i>Australian and New Zealand Journal of Public Health</i> , <b>2020</b> , 44, 219-226	2.3	1
171	Has Human Papillomavirus (HPV) Vaccination Prevented Adverse Pregnancy Outcomes? Population-Level Analysis After 8 Years of a National HPV Vaccination Program in Australia. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 222, 499-508	7	10
170	The past, present and future impact of HIV prevention and control on HPV and cervical disease in Tanzania: A modelling study. <i>PLoS ONE</i> , <b>2020</b> , 15, e0231388	3.7	10
169	Protocol and Rationale for the International Lung Screening Trial. <i>Annals of the American Thoracic Society</i> , <b>2020</b> , 17, 503-512	4.7	20
168	Projected time to elimination of cervical cancer in the USA: a comparative modelling study. <i>Lancet Public Health, The</i> , <b>2020</b> , 5, e213-e222	22.4	30
167	Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study. <i>Lancet Public Health, The</i> , <b>2020</b> , 5, e223-e234	22.4	66
166	Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment. <i>PLoS ONE</i> , <b>2020</b> , 15, e0227899	3.7	7
165	How has COVID-19 impacted cancer screening? Adaptation of services and the future outlook in Australia. <i>Public Health Research and Practice</i> , <b>2020</b> , 30,	5.1	18
164	HPV swab self-collection and cervical cancer in women who have sex with women. <i>Medical Journal of Australia</i> , <b>2020</b> , 213, 239-239.e1	4	4
163	Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. <i>Lancet, The</i> , <b>2020</b> , 395, 575-590 <sup>40</sup>	4 <sup>0</sup>	192
162	Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. <i>Lancet, The</i> , <b>2020</b> , 395, 591-603	4 <sup>0</sup>	145
161	The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome. <i>Medical Journal of Australia</i> , <b>2020</b> , 212, 72-81	4	8
160	The Key Role of Mathematical Modeling and Health Economics in the Public Health Transitions in Cervical Cancer Prevention <b>2020</b> , 333-347		
159	Evaluating health benefits and cost-effectiveness of a mass-media campaign for improving participation in the National Bowel Cancer Screening Program in Australia. <i>Public Health</i> , <b>2020</b> , 179, 90-99 <sup>4</sup>	4 <sup>9</sup>	11
158	Estimating the Natural History of Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative Analysis. <i>Journal of the National Cancer Institute</i> , <b>2020</b> , 112, 955-963	9.7	20
157	Trends in Prescribing Menopausal Hormone Therapy and Bisphosphonates in Australia and Manitoba, Canada and Adherence to Recommendations. <i>Journal of Women's Health</i> , <b>2020</b> , 29, 177-186	3	2
156	The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology. <i>Medical Decision Making</i> , <b>2020</b> , 40, 474-482	2.5	1

155	Historical and projected hysterectomy rates in the USA: Implications for future observed cervical cancer rates and evaluating prevention interventions. <i>Gynecologic Oncology</i> , <b>2020</b> , 158, 710-718	4.9	4
154	Pathways to a cancer-free future: a protocol for modelled evaluations to minimise the future burden of colorectal cancer in Australia. <i>BMJ Open</i> , <b>2020</b> , 10, e036475	3	1
153	Health services costs for lung cancer care in Australia: Estimates from the 45 and Up Study. <i>PLoS ONE</i> , <b>2020</b> , 15, e0238018	3.7	3
152	The health and economic impact of implementation strategies for improving detection of hereditary cancer patients Protocol for an in-depth cost-effectiveness evaluation with microsimulation modelling. <i>Implementation Science Communications</i> , <b>2020</b> , 1,	2.2	1
151	Validation of Microsimulation Models against Alternative Model Predictions and Long-Term Colorectal Cancer Incidence and Mortality Outcomes of Randomized Controlled Trials. <i>Medical Decision Making</i> , <b>2020</b> , 40, 815-829	2.5	5
150	Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis. <i>The Lancet Global Health</i> , <b>2020</b> , 8, e1335-e1344	13.6	22
149	Prevalence of Oral Human Papillomavirus Infection Among Australian Indigenous Adults. <i>JAMA Network Open</i> , <b>2020</b> , 3, e204951	10.4	6
148	Changes in cancer incidence and mortality in Australia over the period 1996-2015. <i>BMC Research Notes</i> , <b>2020</b> , 13, 561	2.3	1
147	The future burden of kidney and bladder cancers preventable by behavior modification in Australia: A pooled cohort study. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 874-883	7.5	5
146	Health services costs for lung cancer care in Australia: Estimates from the 45 and Up Study <b>2020</b> , 15, e0238018		
145	Health services costs for lung cancer care in Australia: Estimates from the 45 and Up Study <b>2020</b> , 15, e0238018		
144	Health services costs for lung cancer care in Australia: Estimates from the 45 and Up Study <b>2020</b> , 15, e0238018		
143	Health services costs for lung cancer care in Australia: Estimates from the 45 and Up Study <b>2020</b> , 15, e0238018		
142	The past, present and future impact of HIV prevention and control on HPV and cervical disease in Tanzania: A modelling study <b>2020</b> , 15, e0231388		
141	The past, present and future impact of HIV prevention and control on HPV and cervical disease in Tanzania: A modelling study <b>2020</b> , 15, e0231388		
140	The past, present and future impact of HIV prevention and control on HPV and cervical disease in Tanzania: A modelling study <b>2020</b> , 15, e0231388		
139	The past, present and future impact of HIV prevention and control on HPV and cervical disease in Tanzania: A modelling study <b>2020</b> , 15, e0231388		
138	Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study. <i>Lancet Public Health</i> , <b>2019</b> , 4, e462-e472	22.4	24

137	Statistical projection methods for lung cancer incidence and mortality: a systematic review. <i>BMJ Open</i> , <b>2019</b> , 9, e028497	3	15
136	HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , <b>2019</b> , 8, 100184	4.6	17
135	Development and application of a framework to estimate health care costs in China: The cervical cancer example. <i>PLoS ONE</i> , <b>2019</b> , 14, e0222760	3.7	3
134	Association of ten gastrointestinal and other medical conditions with positivity to faecal occult blood testing in routine screening: a large prospective study of women in England. <i>International Journal of Epidemiology</i> , <b>2019</b> , 48, 549-558	7.8	2
133	The burden of cervical cancer in Vietnam: Synthesis of the evidence. <i>Cancer Epidemiology</i> , <b>2019</b> , 59, 83-103	10.3	10
132	Towards the global elimination of cervical cancer. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , <b>2019</b> , 8, 100170	4.6	48
131	Cancer elimination thresholds: one size does not fit all - AuthorsPreply. <i>Lancet Public Health</i> , <b>2019</b> , 4, e87	22.4	
130	Towards global elimination of cervical cancer in all groups of women - AuthorsPreply. <i>Lancet Oncology</i> , <b>2019</b> , 20, e239	21.7	
129	Recurrent disease after treatment for cervical pre-cancer: determining whether prophylactic HPV vaccination could play a role in prevention of secondary lesions. <i>Climacteric</i> , <b>2019</b> , 22, 596-602	3.1	5
128	Lung cancer mortality in Australia in the twenty-first century: How many lives can be saved with effective tobacco control?. <i>Lung Cancer</i> , <b>2019</b> , 130, 208-215	5.9	5
127	The burden of pancreatic cancer in Australia attributable to smoking. <i>Medical Journal of Australia</i> , <b>2019</b> , 210, 213-220	4	3
126	The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications. <i>Gynecologic Oncology</i> , <b>2019</b> , 152, 472-479	4.9	2
125	Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia. <i>Gynecologic Oncology</i> , <b>2019</b> , 152, 465-471	4.9	12
124	The preventable burden of endometrial and ovarian cancers in Australia: A pooled cohort study. <i>Gynecologic Oncology</i> , <b>2019</b> , 153, 580-588	4.9	6
123	The preventable burden of breast cancers for premenopausal and postmenopausal women in Australia: A pooled cohort study. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 2383-2394	7.5	8
122	A Prospective Study of Health Conditions Related to Alcohol Consumption Cessation Among 97,852 Drinkers Aged 45 and Over in Australia. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2019</b> , 43, 710-721	3.7	27
121	Spatial variation in cervical cancer screening participation and outcomes among Indigenous and non-Indigenous Australians in Queensland. <i>Geographical Research</i> , <b>2019</b> , 57, 111-122	1.6	3
120	Cancer costs and gender: a snapshot of issues, trends, and opportunities to reduce inequities using Australia as an example. <i>Climacteric</i> , <b>2019</b> , 22, 538-543	3.1	0

119	Comparing theory and non-theory based implementation approaches to improving referral practices in cancer genetics: a cluster randomised trial protocol. <i>Trials</i> , <b>2019</b> , 20, 373	2.8	7
118	Risk of childhood mortality associated with death of a mother in low-and-middle-income countries: a systematic review and meta-analysis. <i>BMC Public Health</i> , <b>2019</b> , 19, 1281	4.1	5
117	Identifying incident cancer cases in routinely collected hospital data: a retrospective validation study. <i>BMC Research Notes</i> , <b>2019</b> , 12, 674	2.3	1
116	Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates. <i>Public Health Research and Practice</i> , <b>2019</b> , 29,	5.1	10
115	Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 394-407	21.7	167
114	Trends in Colon and Rectal Cancer Incidence in Australia from 1982 to 2014: Analysis of Data on Over 375,000 Cases. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2019</b> , 28, 83-90	4	46
113	Clinical Validation of the cobas HPV Test on the cobas 6800 System for the Purpose of Cervical Screening. <i>Journal of Clinical Microbiology</i> , <b>2019</b> , 57,	9.7	12
112	Aboriginal women have a higher risk of cervical abnormalities at screening; South Australia, 1993-2016. <i>Journal of Medical Screening</i> , <b>2019</b> , 26, 104-112	1.4	
111	The projected timeframe until cervical cancer elimination in Australia: a modelling study. <i>Lancet Public Health, The</i> , <b>2019</b> , 4, e19-e27	22.4	160
110	Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 269-282	7.5	21
109	Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia. <i>BMJ Open</i> , <b>2018</b> , 8, e016700	3	15
108	Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1094-1105	8.9	17
107	Cervical screening in HPV-vaccinated populations. <i>Climacteric</i> , <b>2018</b> , 21, 227-234	3.1	7
106	Factors associated with prostate specific antigen testing in Australians: Analysis of the New South Wales 45 and Up Study. <i>Scientific Reports</i> , <b>2018</b> , 8, 4261	4.9	8
105	Health services costs for cancer care in Australia: Estimates from the 45 and Up Study. <i>PLoS ONE</i> , <b>2018</b> , 13, e0201552	3.7	30
104	Patterns of care and emergency presentations for people with non-small cell lung cancer in New South Wales, Australia: A population-based study. <i>Lung Cancer</i> , <b>2018</b> , 122, 171-179	5.9	12
103	Hormonal contraceptive use and smoking as risk factors for high-grade cervical intraepithelial neoplasia in unvaccinated women aged 30-44 years: A case-control study in New South Wales, Australia. <i>Cancer Epidemiology</i> , <b>2018</b> , 55, 162-169	2.8	8
102	The future burden of lung cancer attributable to current modifiable behaviours: a pooled study of seven Australian cohorts. <i>International Journal of Epidemiology</i> , <b>2018</b> , 47, 1772-1783	7.8	6

101	Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia. <i>PLoS ONE</i> , <b>2018</b> , 13, e0185332	3.7	40
100	Human Papillomavirus and Oropharyngeal Cancer Among Indigenous Australians: Protocol for a Prevalence Study of Oral-Related Human Papillomavirus and Cost-Effectiveness of Prevention. <i>JMIR Research Protocols</i> , <b>2018</b> , 7, e10503	2	13
99	Factors associated with participation in colorectal cancer screening in Australia: Results from the 45 and Up Study cohort. <i>Preventive Medicine</i> , <b>2018</b> , 106, 185-193	4.3	15
98	Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales Cancer Lifestyle and Evaluation of Risk (CLEAR) study. <i>PLoS ONE</i> , <b>2018</b> , 13, e0205034	3.7	5
97	The Future Colorectal Cancer Burden Attributable to Modifiable Behaviors: A Pooled Cohort Study. <i>JNCI Cancer Spectrum</i> , <b>2018</b> , 2, pky033	4.6	4
96	Inaccurate and fundamentally flawed analysis risks undermining confidence in cervical screening programs. <i>Journal of the American Society of Cytopathology</i> , <b>2018</b> , 7, 336-338	2.4	1
95	Anal cancer in high-income countries: Increasing burden of disease. <i>PLoS ONE</i> , <b>2018</b> , 13, e0205105	3.7	32
94	Comorbidity and cervical cancer survival of Indigenous and non-Indigenous Australian women: A semi-national registry-based cohort study (2003-2012). <i>PLoS ONE</i> , <b>2018</b> , 13, e0196764	3.7	11
93	Benefits, Harms, and Cost-Effectiveness of Potential Age Extensions to the National Bowel Cancer Screening Program in Australia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2018</b> , 27, 1450-1461	4	14
92	Potential for HPV vaccination and primary HPV screening to reduce cervical cancer disparities: Example from New Zealand. <i>Vaccine</i> , <b>2018</b> , 36, 6314-6324	4.1	2
91	Lung cancer mortality in Australia: Projected outcomes to 2040. <i>Lung Cancer</i> , <b>2018</b> , 125, 68-76	5.9	12
90	Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. <i>Lancet Public Health</i> , <b>2017</b> , 2, e96-e107	22.4	89
89	Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO risk prediction tool. <i>International Journal of Cancer</i> , <b>2017</b> , 141, 242-253	7.5	51
88	Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 2192-2200	7.5	68
87	Impact of the National Cervical Screening Programme in New Zealand by age: analysis of cervical cancer trends 1985-2013 in all women and in Māori women. <i>Cancer Causes and Control</i> , <b>2017</b> , 28, 1393-1404	2.8	12
86	Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. <i>PLoS Medicine</i> , <b>2017</b> , 14, e1002388	11.6	50
85	Time to clinical investigation for Indigenous and non-Indigenous Queensland women after a high grade abnormal Pap smear, 2000-2009. <i>Medical Journal of Australia</i> , <b>2017</b> , 206, 73-77	4	9
84	The burden of cancer attributable to modifiable risk factors: the Australian cancer-PAF cohort consortium. <i>BMJ Open</i> , <b>2017</b> , 7, e016178	3	11

83	Cost-effectiveness estimates: the need for complete reporting - AuthorsPreply. <i>Lancet Public Health, The</i> , <b>2017</b> , 2, e212	22.4	1
82	Projected impact of HPV vaccination and primary HPV screening on cervical adenocarcinoma: Example from Australia. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , <b>2017</b> , 3, 134-141	4.6	13
81	Vulvar cancer in high-income countries: Increasing burden of disease. <i>International Journal of Cancer</i> , <b>2017</b> , 141, 2174-2186	7.5	33
80	A new era for cervical screening in Australia: Watch this space!. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>2017</b> , 57, 499-501	1.7	6
79	How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country. <i>International Journal of Cancer</i> , <b>2017</b> , 141, 2410-2422	7.5	21
78	Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study. <i>Lancet Public Health, The</i> , <b>2017</b> , 2, e331-e340	22.4	63
77	Identifying incident colorectal and lung cancer cases in health service utilisation databases in Australia: a validation study. <i>BMC Medical Informatics and Decision Making</i> , <b>2017</b> , 17, 23	3.6	22
76	Menopausal hormone therapy: a systematic review of cost-effectiveness evaluations. <i>BMC Health Services Research</i> , <b>2017</b> , 17, 326	2.9	4
75	Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia. <i>PLoS ONE</i> , <b>2017</b> , 12, e0163509	3.7	19
74	Resilience of a FIT screening programme against screening fatigue: a modelling study. <i>BMC Public Health</i> , <b>2016</b> , 16, 1009	4.1	8
73	Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use. <i>BMC Health Services Research</i> , <b>2016</b> , 16, 147	2.9	25
72	Menopausal hormone therapy use and breast cancer risk in Australia: Findings from the New South Wales Cancer, Lifestyle and Evaluation of Risk study. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 1905-14	7.5	8
71	Long-Term Impact of the Dutch Colorectal Cancer Screening Program on Cancer Incidence and Mortality-Model-Based Exploration of the Serrated Pathway. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2016</b> , 25, 135-44	4	18
70	Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data. <i>BMC Infectious Diseases</i> , <b>2016</b> , 16, 52	4	15
69	Use of Menopausal Hormone Therapy and Bioidentical Hormone Therapy in Australian Women 50 to 69 Years of Age: Results from a National, Cross-Sectional Study. <i>PLoS ONE</i> , <b>2016</b> , 11, e0146494	3.7	23
68	Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand. <i>PLoS ONE</i> , <b>2016</b> , 11, e0151619	3.7	39
67	Impact of HPV sample self-collection for underscreened women in the renewed Cervical Screening Program. <i>Medical Journal of Australia</i> , <b>2016</b> , 204, 1941e-7	4	24
66	Cervical Abnormalities Are More Common among Indigenous than Other Australian Women: A Retrospective Record-Linkage Study, 2000-2011. <i>PLoS ONE</i> , <b>2016</b> , 11, e0150473	3.7	6

65	Impact of the Australian National Cervical Screening Program in women of different ages. <i>Medical Journal of Australia</i> , <b>2016</b> , 205, 359-364	4	28
64	Using probabilistic record linkage methods to identify Australian Indigenous women on the Queensland Pap Smear Register: the National Indigenous Cervical Screening Project. <i>BMJ Open</i> , <b>2016</b> , 6, e009540	3	11
63	Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. <i>Lancet Public Health, The</i> , <b>2016</b> , 1, e8-e17	22.4	148
62	Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis. <i>Lancet Public Health, The</i> , <b>2016</b> , 1, e66-e75	22.4	28
61	Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries. <i>International Journal of Cancer</i> , <b>2016</b> , 139, 2771-2780	7.5	49
60	Past cervical intraepithelial neoplasia grade 3, obesity, and earlier menopause are associated with an increased risk of vulval cancer in postmenopausal women. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 599-606	8.7	13
59	The molecular characteristics of colonic neoplasms in serrated polyposis: a systematic review and meta-analysis. <i>Journal of Pathology: Clinical Research</i> , <b>2016</b> , 2, 127-37	5.3	10
58	The first comprehensive report on Indigenous Australian women's inequalities in cervical screening: A retrospective registry cohort study in Queensland, Australia (2000-2011). <i>Cancer</i> , <b>2016</b> , 122, 1560-9	6.4	35
57	The Cancer, Lifestyle and Evaluation of Risk Study (CLEAR): Rationale and design of an unmatched "case-spouse control" study of over 10,000 participants in New South Wales, Australia. <i>Cancer Epidemiology</i> , <b>2015</b> , 39, 414-23	2.8	5
56	Pre-vaccination type-specific HPV prevalence in confirmed cervical high grade lesions in the Māori and non-Māori populations in New Zealand. <i>BMC Infectious Diseases</i> , <b>2015</b> , 15, 365	4	2
55	Optimal uptake rates for initial treatments for cervical cancer in concordance with guidelines in Australia and Canada: Results from two large cancer facilities. <i>Cancer Epidemiology</i> , <b>2015</b> , 39, 600-11	2.8	7
54	Factors related to vaccine uptake by young adult women in the catch-up phase of the National HPV Vaccination Program in Australia: Results from an observational study. <i>Vaccine</i> , <b>2015</b> , 33, 2387-94	4.1	19
53	Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 211, 91-9	7	56
52	Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries. <i>Vaccine</i> , <b>2015</b> , 33, 34-54	4.1	5
51	Effect of changes in treatment practice on survival for cervical cancer: results from a population-based study in Manitoba, Canada. <i>BMC Cancer</i> , <b>2015</b> , 15, 642	4.8	8
50	Changing Trends in Vulvar Cancer Incidence and Mortality Rates in Australia Since 1982. <i>International Journal of Gynecological Cancer</i> , <b>2015</b> , 25, 1683-9	3.5	32
49	Long-Term Impact of the Dutch Colorectal Cancer Screening Programme on Cancer Incidence: Exploration of the Serrated Pathway. <i>Value in Health</i> , <b>2014</b> , 17, A323	3.3	1
48	Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program. <i>BMC Infectious Diseases</i> , <b>2014</b> , 14, 351	4	23

47	Testing previous model predictions against new data on human papillomavirus vaccination program outcomes. <i>BMC Research Notes</i> , <b>2014</b> , 7, 109	2.3	11
46	Modeling the Adenoma and Serrated pathway to Colorectal Cancer (ASCCA). <i>Risk Analysis</i> , <b>2014</b> , 34, 889-910	3.9	25
45	High-grade cervical abnormalities and cervical cancer in women following a negative Pap smear with and without an endocervical component: a cohort study with 10 years of follow-up. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 1213-9	7.5	5
44	A survey of population-based utility scores for cervical cancer prevention. <i>BMC Research Notes</i> , <b>2014</b> , 7, 899	2.3	10
43	Human papillomavirus 16/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational study. <i>BMC Infectious Diseases</i> , <b>2014</b> , 14, 3861	4	8
42	Incremental benefits of male HPV vaccination: accounting for inequality in population uptake. <i>PLoS ONE</i> , <b>2014</b> , 9, e101048	3.7	13
41	The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. <i>Health Technology Assessment</i> , <b>2014</b> , 18, 1-196	4.4	88
40	Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand. <i>BMC Infectious Diseases</i> , <b>2013</b> , 13, 114	4	18
39	Cancer incidence and mortality in people aged less than 75 years: changes in Australia over the period 1987-2007. <i>Cancer Epidemiology</i> , <b>2013</b> , 37, 780-7	2.8	15
38	Comprehensive control of human papillomavirus infections and related diseases. <i>Vaccine</i> , <b>2013</b> , 31 Suppl 8, I1-31	4.1	85
37	Comprehensive control of human papillomavirus infections and related diseases. <i>Vaccine</i> , <b>2013</b> , 31 Suppl 7, H1-31	4.1	230
36	Uptake of liquid-based cytology as an adjunct to conventional cytology for cervical screening in NSW, Australia: a cross-sectional and population-based cohort analysis. <i>BMC Public Health</i> , <b>2013</b> , 13, 1196 <sup>4.1</sup>	4.1	1196
35	Comprehensive control of human papillomavirus infections and related diseases. <i>Vaccine</i> , <b>2013</b> , 31 Suppl 5, F1-31	4.1	28
34	Quantifying the impact of dissimilar HPV vaccination uptake among Manitoban school girls by ethnicity using a transmission dynamic model. <i>Vaccine</i> , <b>2013</b> , 31, 4848-55	4.1	11
33	Comprehensive control of human papillomavirus infections and related diseases. <i>Vaccine</i> , <b>2013</b> , 31 Suppl 6, G1-31	4.1	26
32	The impact of a two- versus three-yearly cervical screening interval recommendation on cervical cancer incidence and mortality: an analysis of trends in Australia, New Zealand, and England. <i>Cancer Causes and Control</i> , <b>2013</b> , 24, 1727-36	2.8	18
31	The burden of cervical cancer in China: synthesis of the evidence. <i>International Journal of Cancer</i> , <b>2012</b> , 130, 641-52	7.5	108
30	Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: a micro-costing study. <i>BMC Health Services Research</i> , <b>2012</b> , 12, 123	2.9	30

29	Expenditure and resource utilisation for cervical screening in Australia. <i>BMC Health Services Research</i> , <b>2012</b> , 12, 446	2.9	14
28	Cervical cancer screening in Middle Eastern and Asian migrants to Australia: a record linkage study. <i>Cancer Epidemiology</i> , <b>2012</b> , 36, e394-400	2.8	85
27	Modeling preventative strategies against human papillomavirus-related disease in developed countries. <i>Vaccine</i> , <b>2012</b> , 30 Suppl 5, F157-67	4.1	84
26	Impact of organised cervical screening on cervical cancer incidence and mortality in migrant women in Australia. <i>BMC Cancer</i> , <b>2012</b> , 12, 491	4.8	11
25	A revision of sexual mixing matrices in models of sexually transmitted infection. <i>Statistics in Medicine</i> , <b>2012</b> , 31, 3419-32	2.3	8
24	Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study. <i>PLoS Medicine</i> , <b>2012</b> , 9, e1001182	11.6	62
23	Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS Sentinel Sites Study. <i>BMJ, The</i> , <b>2012</b> , 345, e7086	5.9	27
22	Participation in cervical screening by older asian and middle eastern migrants in new South wales, australia. <i>Health Promotion Perspectives</i> , <b>2012</b> , 2, 274-86	3.1	4
21	Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies. <i>Vaccine</i> , <b>2011</b> , 29, 2487-94	4.1	57
20	The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. <i>Vaccine</i> , <b>2011</b> , 29, 9112-22	4.1	54
19	An epidemiological overview of the relationship between hormone replacement therapy and breast cancer. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2011</b> , 6, 397-409	4.1	8
18	Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. <i>BMC Cancer</i> , <b>2011</b> , 11, 239	4.8	41
17	Recent declines in breast cancer incidence: mounting evidence that reduced use of menopausal hormones is largely responsible. <i>Breast Cancer Research</i> , <b>2010</b> , 12, 103	8.3	9
16	Models of cervical screening in the era of human papillomavirus vaccination. <i>Sexual Health</i> , <b>2010</b> , 7, 359-67		5
15	Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years. <i>BMC Public Health</i> , <b>2010</b> , 10, 734	4.1	29
14	Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis. <i>American Journal of Epidemiology</i> , <b>2009</b> , 170, 24-8	3.8	48
13	Sustained lower rates of HRT prescribing and breast cancer incidence in Australia since 2003. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 117, 671-3	4.4	24
12	Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. <i>Medical Journal of Australia</i> , <b>2009</b> , 190, 164-165	4	

11	Oral Contraceptives, Hormone Replacement Therapy, and Cancers of the Female Reproductive System <b>2009</b> , 111-130		
10	Normal endometrial cells in cervical cytology: systematic review of prevalence and relation to significant endometrial pathology. <i>Journal of Medical Screening</i> , <b>2008</b> , 15, 188-98	1.4	7
9	Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. <i>Medical Journal of Australia</i> , <b>2008</b> , 188, 641-4	4	106
8	The predicted impact of vaccination on human papillomavirus infections in Australia. <i>International Journal of Cancer</i> , <b>2008</b> , 123, 1854-63	7.5	42
7	The agreement between self-reported cervical smear abnormalities and screening programme records. <i>Journal of Medical Screening</i> , <b>2006</b> , 13, 72-5	1.4	11
6	Cervical cancer in Australia and the United Kingdom: comparison of screening policy and uptake, and cancer incidence and mortality. <i>Medical Journal of Australia</i> , <b>2006</b> , 185, 482-6	4	85
5	Factors predicting successful DNA recovery from archival cervical smear samples. <i>Cytopathology</i> , <b>2004</b> , 15, 276-82	1.3	13
4	The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. <i>British Journal of Cancer</i> , <b>2004</b> , 91, 530-6	8.7	71
3	A real time optoelectronic device as an adjunct to the Pap smear for cervical screening: a multicenter evaluation. <i>International Journal of Gynecological Cancer</i> , <b>2003</b> , 13, 804-11	3.5	33
2	Real-Time Devices for the Screening and Diagnosis of Cervical Neoplasia 387-398		1
1	HPV screening for cervical cancer is reaching maturity. <i>BMJ</i> , <b>The</b> , 01303	5.9	0